Aprea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hamill John P.
Aprea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Gilad Oren
Aprea Therapeutics | 8-K: Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Aprea Therapeutics | 10-K: Annual report
Aprea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hamill John P.
Aprea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Seizinger Bernd R.
Aprea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HENNEMAN JOHN B III
Aprea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Gilad Oren
Aprea Therapeutics | 8-K: Current report
Aprea Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sio Capital Management, LLC(7.49%)
Aprea Therapeutics | 424B3: Prospectus
Aprea Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-AIGH Capital Management, LLC(9.4%),Orin H(9.4%)
Aprea Therapeutics | 8-K: Current report
Aprea Therapeutics | 424B3: Prospectus
Aprea Therapeutics | EFFECT: Others
Aprea Therapeutics | 8-K: Current report
Aprea Therapeutics | CORRESP: CORRESP
Aprea Therapeutics | UPLOAD: Others
Aprea Therapeutics | 8-K: Current report
Aprea Therapeutics | S-3: Registration statement for specified transactions by certain issuers
No Data